Rachel Haurwitz
President and Chief Executive Officer, Caribou Biosciences
Meet Rachel Haurwitz
Rachel has a research background in CRISPR-Cas biology and holds several patents covering CRISPR-derived technologies. She co-founded Caribou in 2012 and Intellia Therapeutics in 2014, both of which are developing genome editing therapies. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business.